Business Description
Onconetix Inc
NAICS : 541713
SIC : 2834
ISIN : US09610B1089
Total Employee Number:
2Description
Onconetix Inc. is a commercial-stage biotechnology company focused on diagnostics and therapeutics for men's health and oncology. Its principal product is Proclarix, an in vitro diagnostic blood test that aids in assessing the risk of clinically significant prostate cancer, helping to reduce unnecessary biopsies. Proclarix holds CE marking for sale in the European Union and is marketed in the United States as a laboratory-developed test. The company also has pursued development programs in men's health, including a topical formulation for erectile dysfunction. Onconetix sells primarily to clinical laboratories, urology practices, and healthcare providers, generating revenue through product sales and diagnostic testing services. Its commercial operations are concentrated in Europe, particularly Switzerland and the United Kingdom, with efforts to expand adoption of its diagnostic offerings in the U.S. market.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 31.78 | |||||
Equity-to-Asset | 0.82 | |||||
Debt-to-Equity | 0.01 | |||||
Debt-to-EBITDA | -0.02 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | -12.81 | |||||
Beneish M-Score | -1.42 | |||||
WACC vs ROIC | ||||||
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 2.21 | |||||
Quick Ratio | 2.14 | |||||
Cash Ratio | 2.02 | |||||
Days Inventory | 461.57 | |||||
Days Sales Outstanding | 40.46 | |||||
Days Payable | 5473.28 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 80.34 | |||||
Operating Margin % | -1189.94 | |||||
Net Margin % | -1578.33 | |||||
EBITDA Margin % | -1527.71 | |||||
FCF Margin % | -1602.9 | |||||
OCF Margin % | -1602.9 | |||||
ROE % | -101.41 | |||||
ROA % | -53.67 | |||||
ROIC % | -35.59 | |||||
3-Year ROIIC % | 28.84 | |||||
ROC (Joel Greenblatt) % | -14667.66 | |||||
ROCE % | -97.22 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 5 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 0.04 | |||||
PB Ratio | 0.21 | |||||
Price-to-Tangible-Book | 0.73 | |||||
EV-to-EBIT | 0.3 | |||||
EV-to-EBITDA | 0.3 | |||||
EV-to-Revenue | -4.51 | |||||
EV-to-FCF | 0.24 | |||||
| Price-to-Net-Current-Asset-Value | 0.8 | |||||
| Price-to-Net-Cash | 0.95 | |||||
Earnings Yield (Greenblatt) % | 339.78 | |||||
FCF Yield % | -354.79 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Onconetix Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 0.552 | ||
| EPS (TTM) (€) | -170.212 | ||
| Beta | 0.1732 | ||
| 3-Year Sharpe Ratio | -0.7 | ||
| 3-Year Sortino Ratio | -1.08 | ||
| Volatility % | - | ||
| 14-Day RSI | - | ||
| 14-Day ATR (€) | - | ||
| 20-Day SMA (€) | 10880 | ||
| 12-1 Month Momentum % | - | ||
| 52-Week Range (€) | 10880 - 10880 | ||
| Shares Outstanding (Mil) | 4.38 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Onconetix Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Onconetix Inc Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| Annual report for 2026 | 2027-03-12 | In 171 days | ||
| General meeting for 2026 | 2026-12-04 11:00 | In 74 days | ||
| Third quarter earnings results for 2026 | 2026-11-13 | In 52 days | ||
| Second quarter earnings results for 2026 | 2026-08-14 | 12,070.00 (-29.00%) | ||
| 0.1:1 Stock Split | 2026-05-21 | 12,070.00 (-29.00%) | ||
| First quarter earnings results for 2026 | 2026-05-13 | 12,070.00 (-29.00%) | ||
| 0.2:1 Stock Split | 2026-03-25 | 12,070.00 (-29.00%) | ||
| Annual report for 2025 | 2026-03-13 | 12,070.00 (-29.00%) | ||
| General meeting for 2025 | 2025-12-05 11:00 | 12,070.00 (-29.00%) | ||
| Third quarter earnings results for 2025 | 2025-11-13 | 12,070.00 (-29.00%) |
Show
Entries
Onconetix Inc Frequently Asked Questions
What is Onconetix Inc(STU:J4T)'s stock price today?
The current price of STU:J4T is €10880.00. The 52 week high of STU:J4T is €10880.00 and 52 week low is €10880.00.
When is next earnings date of Onconetix Inc(STU:J4T)?
The next earnings date of Onconetix Inc(STU:J4T) is 2026-11-13 Est..
Does Onconetix Inc(STU:J4T) pay dividends? If so, how much?
Onconetix Inc(STU:J4T) does not pay dividend.
Press Release
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers